Morgan Stanley Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $4

Futu NewsNov 8 22:31 · Ratings

Morgan Stanley Remains a Hold on Editas Medicine (EDIT)

TipRanksNov 8 22:28 · Ratings

Editas Medicine Upgraded at Evercore on CRISPR Platform

Seeking AlphaNov 7 02:59

Evercore Upgrades Editas Medicine(EDIT.US) to Buy Rating, Maintains Target Price $7

Futu NewsNov 7 01:31 · Ratings

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswireNov 6 22:00

A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $5 to $13

Futu NewsNov 6 21:00 · Ratings